512 related articles for article (PubMed ID: 25922549)
21. Health-related quality of life in patients with long-standing rheumatoid arthritis in the era of biologics: data from the German biologics register RABBIT.
Gerhold K; Richter A; Schneider M; Bergerhausen HJ; Demary W; Liebhaber A; Listing J; Zink A; Strangfeld A
Rheumatology (Oxford); 2015 Oct; 54(10):1858-66. PubMed ID: 26001633
[TBL] [Abstract][Full Text] [Related]
22. Monotherapy is a relevant option in rheumatoid arthritis treatment: a literature review.
Doria A; Zavaglia D
Clin Exp Rheumatol; 2019; 37(5):862-871. PubMed ID: 31376250
[TBL] [Abstract][Full Text] [Related]
23. Clinical and therapeutic management of rheumatoid arthritis with biological disease-modifying antirheumatic drugs: RADAR study.
Gomez-Centeno A; Rubio-Romero E; Ovalles JG; Manrique-Arija S; Marsal-Barril S; Amarelo-Ramos J; Del Pino-Montes J; Muñoz-Fernández S; Bustabad S; Barbazán-Álvarez C
Rheumatol Int; 2019 Dec; 39(12):2015-2024. PubMed ID: 31396685
[TBL] [Abstract][Full Text] [Related]
24. Diagnosis and treatment of rheumatoid arthritis in the Emilia Romagna region: a prospective population-based study.
Addimanda O; Marino M; Farina I; Trevisani M; Arrigoni E; Lumetti F; Crescentini F; Sambo P; Bezzi A; Bruschi M; Santilli D; Reta M; Bosi S; Delsante G; Girelli F; Montaguti L; Meliconi R; Sebastiani M; Ferri C; Malavolta N; Govoni M; Trombetti S; De Palma R; Salvarani C
Clin Exp Rheumatol; 2017; 35(2):201-208. PubMed ID: 28134078
[TBL] [Abstract][Full Text] [Related]
25. Impact of multimorbidity on the first ts/bDMARD effectiveness and retention rate after two years of follow-up in patients with rheumatoid arthritis from the BIOBADASER registry.
Calvo-Gutiérrez J; López-Medina C; Otero-Varela L; Escudero-Contreras A; Ortega-Castro R; Ladehesa-Pineda L; Campos C; Bernabeu-Gonzalvez P; Pérez-Gómez A; García-Dorta A; Ruiz-Montesino D; Pombo-Suarez M; Ros-Vilamajo I; Sánchez-Alonso F; Castrejón I
Arthritis Res Ther; 2024 Feb; 26(1):57. PubMed ID: 38395899
[TBL] [Abstract][Full Text] [Related]
26. Psoriatic arthritis treatment regimens, therapy duration and reasons for cessation in the biologics era: a multi-centre Australian study.
Tymms K; Kelly A; Bird P; Griffiths H; de Jager J; Littlejohn G; Louw S; Roberts L; Youssef P; Zochling J; Nichols D
Int J Rheum Dis; 2018 Feb; 21(2):510-516. PubMed ID: 28730757
[TBL] [Abstract][Full Text] [Related]
27. Lymphoma risks in patients with rheumatoid arthritis treated with biological drugs-a Swedish cohort study of risks by time, drug and lymphoma subtype.
Hellgren K; Di Giuseppe D; Smedby KE; Sundström C; Askling J; Baecklund E;
Rheumatology (Oxford); 2021 Feb; 60(2):809-819. PubMed ID: 32810256
[TBL] [Abstract][Full Text] [Related]
28. Economic Burden and Treatment Patterns of Cycling between Conventional Synthetic Disease-modifying Antirheumatic Drugs Among Biologic-treated Patients with Rheumatoid Arthritis.
Betts KA; Griffith J; Ganguli A; Li N; Douglas K; Wu EQ
Clin Ther; 2016 May; 38(5):1205-16. PubMed ID: 27045991
[TBL] [Abstract][Full Text] [Related]
29. Real-world evaluation of TNF-inhibitor utilization in rheumatoid arthritis.
Harnett J; Wiederkehr D; Gerber R; Gruben D; Koenig A; Bourret J
J Med Econ; 2016; 19(2):91-102. PubMed ID: 26401963
[TBL] [Abstract][Full Text] [Related]
30. Effect of Concomitant Disease-modifying Antirheumatic Drugs and Methotrexate Administration Route on Biologic Treatment Durability in Rheumatoid Arthritis: OBRI Cohort Results.
Lau AN; Thorne JC; Movahedi M; Rampakakis E; Cesta A; Li X; Couto S; Sampalis J; Bombardier C;
J Rheumatol; 2019 Aug; 46(8):874-886. PubMed ID: 30988121
[TBL] [Abstract][Full Text] [Related]
31. Treatment strategies in patients with rheumatoid arthritis for whom methotrexate monotherapy has failed: data from the NOR-DMARD register.
Lie E; van der Heijde D; Uhlig T; Mikkelsen K; Kalstad S; Kaufmann C; Rødevand E; Kvien TK
Ann Rheum Dis; 2011 Dec; 70(12):2103-10. PubMed ID: 21875874
[TBL] [Abstract][Full Text] [Related]
32. Low rates of biologic-free clinical disease activity index remission maintenance after biologic disease-modifying anti-rheumatic drug discontinuation while in remission in a Japanese multicentre rheumatoid arthritis registry.
Yoshida K; Kishimoto M; Radner H; Matsui K; Okada M; Saeki Y; Solomon DH; Tohma S
Rheumatology (Oxford); 2016 Feb; 55(2):286-90. PubMed ID: 26350484
[TBL] [Abstract][Full Text] [Related]
33. Cotreatment with methotrexate in routine care patients with rheumatoid arthritis receiving biological treatment yields better outcomes over time.
Boone NW; Sepriano A; van der Kuy PH; Janknegt R; Peeters R; Landewé RBM
RMD Open; 2019; 5(1):e000836. PubMed ID: 30740244
[TBL] [Abstract][Full Text] [Related]
34. The persistence of golimumab compared to other tumour necrosis factor-α inhibitors in daily clinical practice for the treatment of rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis: observations from the Slovenian nation-wide longitudinal registry of patients treated with biologic disease-modifying antirheumatic drugs-BioRx.si.
Rotar Ž; Tomšič M; Praprotnik S;
Clin Rheumatol; 2019 Feb; 38(2):297-305. PubMed ID: 30324406
[TBL] [Abstract][Full Text] [Related]
35. Real-world treatment persistence in patients with rheumatoid arthritis initiating DMARDs in Germany-a health insurance claims data analysis.
Fiehn C; Zinke S; Haas JS; Meise D; Theil J; Gurrath M; Orzechowski HD
Z Rheumatol; 2023 Nov; 82(9):739-753. PubMed ID: 36757417
[TBL] [Abstract][Full Text] [Related]
36. Less educated and older patients have reduced access to biologic DMARDs even in a country with highly developed social welfare (Norway): results from Norwegian cohort study NOR-DMARD.
Putrik P; Ramiro S; Lie E; Keszei AP; Kvien TK; van der Heijde D; Landewé R; Uhlig T; Boonen A
Rheumatology (Oxford); 2016 Jul; 55(7):1217-24. PubMed ID: 27012686
[TBL] [Abstract][Full Text] [Related]
37. Comparisons between comorbid conditions and health care consumption in rheumatoid arthritis patients with or without biological disease-modifying anti-rheumatic drugs: a register-based study.
Bengtsson K; Jacobsson LT; Rydberg B; Kvist G; Torstenson T; Dehlin M; Hilme E; Lindhé A; Wallerstedt SM; Forsblad-d'Elia H
BMC Musculoskelet Disord; 2016 Dec; 17(1):499. PubMed ID: 27955647
[TBL] [Abstract][Full Text] [Related]
38. Efficacy of biological disease-modifying antirheumatic drugs: a systematic literature review informing the 2016 update of the EULAR recommendations for the management of rheumatoid arthritis.
Nam JL; Takase-Minegishi K; Ramiro S; Chatzidionysiou K; Smolen JS; van der Heijde D; Bijlsma JW; Burmester GR; Dougados M; Scholte-Voshaar M; van Vollenhoven R; Landewé R
Ann Rheum Dis; 2017 Jun; 76(6):1113-1136. PubMed ID: 28283512
[TBL] [Abstract][Full Text] [Related]
39. Real-world clinical experience of biological disease modifying anti-rheumatic drugs in Malaysia rheumatoid arthritis patients.
Tan BE; Lim AL; Kan SL; Lim CH; Tsang EEL; Ch'ng SS; Mohd Noor N; Mohd Jamid N; Teh CL; Joshua Thundyil R; Loh YL; Chong HC; Ong SG; Mohamed Ismail A; Lee YYL; Gun SC
Rheumatol Int; 2017 Oct; 37(10):1719-1725. PubMed ID: 28695274
[TBL] [Abstract][Full Text] [Related]
40. Increased radiographic progression of distal hand osteoarthritis occurring during biologic DMARD monotherapy for concomitant rheumatoid arthritis.
Lechtenboehmer CA; Burkard T; Reichenbach S; Walker UA; Burden AM; Hügle T
Arthritis Res Ther; 2021 Oct; 23(1):267. PubMed ID: 34702319
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
